Dendreon (DNDN) Moves Higher After FDA Approves Expanded Manufacturing
Tweet Send to a FriendGet Alerts DNDN Hot Sheet
Down)
Trade DNDN Now!
Dendreon (Nasdaq: DNDN) moved higher intra-day following news that the FDA approved the remainder of its New Jersey manufacturing facility, allowing the company to significantly increase the availability of PROVENGE.
Shares are currently up 3.3 percent on the news.
With the FDA approval of 36 additional workstations, the New Jersey facility will now have a total of 48 approved workstations.
In anticipation of the availability of the additional workstations, Dendreon expects to have approximately 225 infusion centers prepared to treat their first patient by the end of Q2, approximately 450 infusion centers upon entering Q4, and approximately 500 by the end of 2011.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Shares are currently up 3.3 percent on the news.
With the FDA approval of 36 additional workstations, the New Jersey facility will now have a total of 48 approved workstations.
In anticipation of the availability of the additional workstations, Dendreon expects to have approximately 225 infusion centers prepared to treat their first patient by the end of Q2, approximately 450 infusion centers upon entering Q4, and approximately 500 by the end of 2011.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Analyst Sees Potential for Omeros' (OMER) OMS824 as FDA Gives Clearance
- EMA Approves MAA for Gilead's (GILD) Sofosbuvir
- AcelRx Pharma (ACRX) Stock Higher; Sufentanil NanoTab Study Meets Primary Endpoint
Create E-mail Alert Related Categories
FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
